Keywords
How to Cite
Abstract views: 422 PDF Downloads: 137
Abstract
Irritable bowel syndrome (IBS) is a functional pathology, the prevalence of which has recently increased significantly in our country, with a corresponding rise in the number of male patients and the predominance of the psycho-emotional factor in the genesis of the disease. The development of IBS is a consequence of the dysfunction of a bidirectional pathway known as the “probiotics — gut — brain” axis. Microbial communities inhabiting the intestines take an active part in ensuring gastrointestinal health as well as in the formation and maintenance of mental health.
Probiotics, in particular psychobiotics that synthesize several neurotransmitters and neuromediators, are recognized as one of the key factors determining the successful functioning of the “probiotics-gut-brain” axis. It is suggested that psychobiotics produce bacterial extracellular microvesicles that can be absorbed from the gastrointestinal tract, enter the brain, deliver their intracellular contents to the central nervous system, improve neuronal function, and probably also provide astrocytes with glycolytic enzymes that contribute to neuroprotection. Some probiotic strains/mixtures simultaneously have a positive effect on the state of the enteric and central nervous systems, reducing the symptoms of IBS and reducing stress, anxiety, and depression. The article presents evidence of the highest level — meta-analyses and systematic reviews — that confirm the efficacy and safety of the use of probiotics in IBS treatment and reveal the molecular mechanisms of action of psychobiotics.
Probiotic Lactiale® Multi, based on a prototype with proven efficacy and safety, contains 14 probiotic strains that help improve the condition of patients with IBS, reduce abdominal pain, and improve the quality of life of patients. Probiotic Lactiale® Multi is theoretically able to improve the psycho-emotional state of patients due to the microorganisms that synthesize various neurotransmitters. Probiotic Lactiale® Multi can be considered the first national psychobiotic with proven effectiveness, indirectly recommended by World Gastroenterology Organisation experts for the treatment of IBS.
References
Інструкція з використання «Лактіалє® Мульті». URL: https://farmak.ua/wp-content/uploads/2020/01/laktiale-multi-instr-290323_300323.pdf (дата звернення: 03.01.2024).
Нагурна Я. В. Перший досвід вивчення поширеності синдрому подразненого кишечнику в окремих районах західного регіону України. СГ. 2014. № 3 (77). С. 27–31.
Скрипник І. М., Криворучко І. Г., Гопко О. Ф. Вплив Bifidobacterium infantis 35624 на клінічний перебіг синдрому подразненого кишечнику залежно від фенотипу: результати локального неінтервенційного проспективного епідеміологічного дослідження «СПК-Контроль». СГ. 2020. № 4 (113). С. 13–21.
Almario C. V., Sharabi E., Chey W., Lauzon M., Higgins C. S., Spiegel B. M. Prevalence and burden of illness of Rome IV irritable bowel syndrome in the United States: Results from a nationwide cross-sectional study. Gastroenterology. 2023. Vol. 165, No 6. P. 1475–1487.
Arnaout A. Y., Nerabani Y., Douba Z., Kassem L. H., Arnaout K., Shabouk M. B., Zayat H., Mayo W., Bezo Y., Arnaout I., Yousef A. The prevalence and risk factors of irritable bowel syndrome (PRIBS study) among adults in low- and middle-income countries: A multicenter cross-sectional study. Health Sci. Rep. 2023. Vol. 6, No 10. P. e1592.
Bleibel L., Dziomba S., Waleron K., Kowalczyk E., Karbownik M. S. Deciphering psychobiotics’ mechanism of action: bacterial extracellular vesicles in the spotlight. Front. Microbiol. 2023. Vol. 14. P. 1211447.
Bolen B. Irritable Bowel Syndrome in U.S. Veterans, 2023. URL: https://www.verywellhealth.com/ibs-in-veterans-1944720 (Last accessed: 03.01.2024).
Bubeck M., Becker C., Patankar J. Guardians of the gut: influence of the enteric nervous system on the intestinal epithelial barrier. Front. Med (Lausanne). 2023. Vol. 10. P. 1228938.
Ceccherini C., Daniotti S., Bearzi C., Re I. Evaluating the efficacy of probiotics in treatment using a systematic review of clinical trials and multi-criteria decision analysis. Nutrients. 2022. Vol. 14, No 13. P. 2689.
Chen D., Zhang Y., Huang T., Jia J. Depression and risk of gastrointestinal disorders: a comprehensive two-sample Mendelian randomization study of European ancestry. Psychol. Med. 2023. P. 1–13.
Choudhary S., Shanu K., Devi S. Psychobiotics as an Emerging Category of Probiotic Products. In: Kothari V., Kumar P., Ray S. (eds.). Probiotics, Prebiotics, Synbiotics, and Postbiotics. Singapore: Springer, 2023. P. 361–391.
Dahiya D., Nigam P. Biotherapy using probiotics as therapeutic agents to restore the gut microbiota to relieve gastrointestinal tract inflammation, IBD, IBS and prevent induction of cancer. Int. J. Mol. Sci. 2023. Vol. 24, No 6. P. 5748.
Diao Z., Xu W., Guo D., Zhang J., Zhang R., Liu F., Hu Y., Ma Y. Causal association between psycho-psychological factors, such as stress, anxiety, depression, and irritable bowel syndrome: Mendelian randomization. Medicine (Baltimore). 2023. Vol. 102, No 34. P. e34802.
Dudzińska E., Grabrucker A., Kwiatkowski P., Sitarz R., Sienkiewicz M. the importance of visceral hypersensitivity in irritable bowel syndrome-plant metabolites in IBS treatment. Pharmaceuticals (Basel). 2023. Vol. 16, No 10. P. 1405.
Facts about IBS. URL: https://aboutibs.org/what-is-ibs/facts-about-ibs/#:~:text=Facts%20about%20IBS,older%20adults%20suffer%20as%20well (Last accessed: 03.01.2024).
Fossey М., Serdyuk А., Markovska А. Ukraine war: conflict-related PTSD is putting strain on an already underfunded mental health system, 2023. URL: https://theconversation.com/ukraine-war-conflict-related-ptsd-is-putting-strain-on-an-already-underfunded-mental-health-system-199629 (Last accessed: 03.01.2024).
Goodoory V. C., Khasawneh M., Black C., Quigley E. M., Moayyedi P., Ford A. C. Efficacy of probiotics in irritable bowel syndrome: systematic review and meta-analysis. Gastroenterology. 2023. Vol. 165, No 5. P. 1206–1218.
Guarner F., Sanders M. E., Szajewska H., Cohen H., Eliakim R., Herrera C., Karakan T., Merenstein D., Piscoya A., Ramakrishna B., Salminen S. World Gastroenterology Organisation Global Guidelines: Probiotics and Prebiotics. World Gastroenterology Organization, February 2023. URL: https://www.worldgastroenterology.org/UserFiles/file/guidelines/probiotics-and-prebiotics-english-2023.pdf (Last accessed: 03.01.2024).
Irritable Bowel Syndrome. War Related Illness and Injury Study Center. URL: https://www.warrelatedillness.va.gov/warrelatedillness/education/healthconditions/irritable-bowel-syndrome.asp (Last accessed: 03.01.2024).
IBS Facts and Statistics. URL: https://aboutibs.org/what-is-ibs/facts-about-ibs/#:~:text=Facts%20about%20IBS,older%20adults%20suffer%20as%20well (Last accessed: 03.01.2024).
Ishaque S. M., Khosruzzaman S., Ahmed D., Sah M. P. A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult®) in the management of diarrhea-predominant irritable bowel syndrome. BMC Gastroenterol. 2018. Vol. 18, No 1. P. 71.
Konstantis G., Efstathiou S., Pourzitaki C., Elisavet K., Georgios G., Michail C. Efficacy and safety of probiotics in the treatment of irritable bowel syndrome: a systematic review and meta-analysis of randomised clinical trials using ROME IV criteria. Clin. Nutr. 2023. Vol. 42, No 5. P. 800–809.
Maiuolo J., Gliozzi M., Musolino V., Carresi C., Scarano F., Nucera S., Scicchitano M., Oppedisano F., Bosco F., Ruga S., Zito M. C. The contribution of gut microbiota — brain axis in the development of brain disorders. Front. Neurosci. 2021. Vol. 15. P. 616883.
Michel K., Kuch B., Dengler S., Demir I. E., Zeller F., Schemann M. How big is the little brain in the gut? Neuronal numbers in the enteric nervous system of mice, Guinea pig, and human. Neurogastroenterol. Motil. 2022. Vol. 34, No 12. P. e14440.
Montagnani M., Bottalico L., Potenza M., Charitos I. A., Topi S., Colella M., Santacroce L. The crosstalk between gut microbiota and nervous system: a bidirectional interaction between microorganisms and metabolome. Int. J. Mol. Sci. 2023. Vol. 24, No 12. P. 10322.
Niu H. L., Xiao J. Y. The efficacy and safety of probiotics in patients with irritable bowel syndrome: Evidence based on 35 randomized controlled trials. Int. J. Surg. 2020. Vol. 75. P. 116–127.
Oka P., Parr H., Barberio B., Black C. J., Savarino E. V., Ford A. C. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 2020. Vol. 5, No 10. P. 908–917.
Oroojzadeh P., Bostanabad S. Y., Lotfi H. Psychobiotics: the influence of gut microbiota on the gut-brain axis in neurological disorders. J. Mol. Neurosci. 2022. Vol. 72, No 9. P. 1952–1964.
Ross K. Psychobiotics: Are they the future intervention for managing depression and anxiety? A literature review. Explore (NY). 2023. Vol. 19, No 5. P. 669–680.
Shang X., E F. F., Guo K., Li Y. F., Zhao H. L., Wang Y., Chen N., Nian T., Yang C. Q., Yang K. H., Li X. X. Effectiveness and safety of probiotics for patients with constipation-predominant irritable bowel syndrome: A systematic review and meta-analysis of 10 randomized controlled trials. Nutrients. 2022. Vol. 14, No 12. P. 2482.
Shrestha B., Patel D., Shah H., Hanna K. S., Kaur H., Alazzeh M. S., Thandavaram A., Channar A., Purohit A., Venugopal S. The role of gut-microbiota in the pathophysiology and therapy of irritable bowel syndrome: A systematic review. Cureus. 2022. Vol. 14, No 8. P. e28064.
Sikorska M., Antosik-Wójcińska A., Dominiak M. Probiotics as a tool for regulating molecular mechanisms in depression: A systematic review and meta-analysis of randomized clinical trials. Int. J. Mol. Sci. 2023. Vol. 24, No 4. P. 3081.
Skowron K., Budzyńska A., Wiktorczyk-Kapischke N., Chomacka K., Grudlewska-Buda K., Wilk M., Wałecka-Zacharska E., Andrzejewska M., Gospodarek-Komkowska E. The role of psychobiotics in supporting the treatment of disturbances in the functioning of the nervous system — a systematic review. Int. J. Mol. Sci. 2022. Vol. 23, No 14. P. 7820.
Sudo N., Chida Y., Aiba Y., Sonoda J., Oyama N., Yu X. N., Kubo C., Koga Y. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. J. Physiol. 2004. Vol. 558, Pt 1. P. 263–275.
Sun J. R., Kong C. F., Qu X., Deng C., Lou Y. N., Jia L. Q. Efficacy and safety of probiotics in irritable bowel syndrome: A systematic review and meta-analysis. Saudi J. Gastroenterol. 2020. Vol. 26, No 2. P. 66–77.
Tarar Z. I., Farooq U., Zafar Y., Gandhi M., Raza S., Kamal F., Tarar M. F., Ghouri Y. A. Burden of anxiety and depression among hospitalized patients with irritable bowel syndrome: a nationwide analysis. Ir. J. Med. Sci. 2023. Vol. 192, No 5. P. 2159–2166.
Trzeciak P., Herbet M. Role of the intestinal microbiome, intestinal barrier and psychobiotics in depression. Nutrients. 2021. Vol. 13, No 3. P. 927.
van der Geest A. M., Schukking I., Brummer R., van de Burgwal L. H., Larsen O. F. Comparing probiotic and drug interventions in irritable bowel syndrome: A meta-analysis of randomised controlled trials. Benef. Microbes. 2022. Vol. 13, No 3. P. 183–194.
van der Schoot A., Helander C., Whelan K., Dimidi E. Probiotics and synbiotics in chronic constipation in adults: A systematic review and meta-analysis of randomized controlled trials. Clin. Nutr. 2022. Vol. 41, No 12. P. 2759–2777.
Wang X., Tang R., Wei Z., Zhan Y., Lu J., Li Z. The enteric nervous system deficits in autism spectrum disorder. Front. Neurosci. 2023. Vol. 17. P. 1101071.
Wang Y., Chen N., Niu F., Li Y., Guo K., Shang X., E F., Yang C., Yang K., Li X Int. J. Colorectal Dis. 2022. Vol. 37, No 11. P. 2263–2276.
Wang Z., Peng Y., Chen M., Peng L., Huang Y., Lin W. The prevalence of irritable bowel syndrome after severe acute respiratory syndrome coronavirus 2 infection and their association: A systematic review and meta-analysis of observational studies. J. Clin. Med. 2023. Vol. 12, No 5. P. 1865.
Wen Y., Li J., Long Q., Yue C. C., He B., Tang X. G. The efficacy and safety of probiotics for patients with constipation-predominant irritable bowel syndrome: A systematic review and meta-analysis based on seventeen randomized controlled trials. Int. J. Surg. 2020. Vol. 79. P. 111–119.
Xie C. R., Tang B., Shi Y., Peng W. Y., Ye K., Tao Q. F., Yu S. G., Zheng H., Chen M. Low FODMAP diet and probiotics in irritable bowel syndrome: A systematic review with network meta-analysis. Front. Pharmacol. 2022. Vol. 13. P. 853011.
Xie P., Luo M., Deng X., Fan J., Xiong L. Outcome-specific efficacy of different probiotic strains and mixtures in irritable bowel syndrome: A systematic review and network meta-analysis. Nutrients. 2023. Vol. 15, No 17. P. 3856.
Zhang W. X., Shi L. B., Zhou M., Wu J., Shi H. Y. Efficacy of probiotics, prebiotics and synbiotics in irritable bowel syndrome: A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials. J. Med. Microbiol. 2023. Vol. 72, No 9. P. 001758.